Ziagen

(Abacavir sulfate)

PreclinicalSmall molecule

Abacavir sulfate is used to treat HIV infection by helping to slow down the virus's ability to multiply in the body. It is typically taken as part of a combination treatment with other HIV medications.[1] Ziagen is currently being investigated across 4 indications[3], with its most advanced program in Preclinical.[1]

Ziagen is one of 131 small molecule programs targeting HIV-1 infection. It is currently in Preclinical.

Indications

Total Trials

Active Trials

130

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIV-1 InfectionUnknown

Immunodeficiency DiseaseUnknown

AdultCompleted

ChildrenCompleted

HIV-1 InfectionPreclinical

Unknown

Immunodeficiency DiseasePreclinical

Unknown

AdultPreclinical

Completed

ChildrenPreclinical

Completed

Competition

Competitive Landscape

127 competitors in Adult

#DrugCompanyPhaseTrials

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 2

Tebrazid

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Phase 3

1 3

Mounjaro

Eli Lilly

Phase 2

1 4

Rifampicin

Boehringer Ingelheim

Phase 3

3 5

Myqorzo

CCytokinetics

Phase 3

1 6

Opzelura

DDizal Pharmaceuticals

Phase 2

1 7

NM8074

NNovelMed Therapeutics

Phase 2

2 8

EB-1020

Otsuka

Phase 3

1 9

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 1

1 10

Ansaid

PPharmacia and Upjohn

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Effectiveness11 trials

The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors

Completed· GSK logo

GSK·Phase 2·NCT00002213·80 enrolled

The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs

Completed· GSK logo

GSK·Phase 3·NCT00002391

A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000922·1,710 enrolled

Show 8 more trials

Safety and Effectiveness of a Combination Anti-HIV Drug Treatment

Completed· GSK logo

GSK·Phase 4·NCT00005018·150 enrolled

A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients

Completed· GSK logo

GSK·Phase 2·NCT00002390

A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults

Completed· GSK logo

GSK·Phase 4·NCT00004585·40 enrolled

Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir)

Unknown status· GSK logo

GSK·Phase 3·NCT00004981·230 enrolled

The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs

Completed· GSK logo

GSK·Phase 3·NCT00002389·210 enrolled

Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment

Unknown status· GSK logo

GSK·Phase 4·NCT00005017·300 enrolled

Effectiveness of the Early Addition of Abacavir to an Anti-HIV Drug Combination

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001132·80 enrolled

Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment

Completed· Gilead logo

Gilead·Phase 2·NCT00002419·25 enrolled

Drug9 trials

A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs

Completed· GSK logo

GSK·N/A·NCT00002217

A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Suspended·TTriangle Pharmaceuticals·Phase 3·NCT00002362

A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients

Completed· GSK logo

GSK·Phase 4·NCT00005106·230 enrolled

Show 6 more trials

A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00102206·6 enrolled

A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000912·475 enrolled

A Study of 1592U89 Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs

Completed· GSK logo

GSK·Phase 2·NCT00002364·40 enrolled

Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs

Unknown status· GSK logo

GSK·Phase 3·NCT00009061·624 enrolled

A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir

Completed· GSK logo

GSK·Phase 2·NCT00002423·100 enrolled

A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Completed· GSK logo

GSK·Phase 2·NCT00002440·80 enrolled

Treatment7 trials

Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000885·440 enrolled

Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00028314·150 enrolled

The Effect of Teaching HIV-Infected Patients About HIV and Treatment

Completed· GSK logo

GSK·Phase 3·NCT00002409·200 enrolled

Show 4 more trials

Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000940·121 enrolled

A Comparison of Two Multi-Drug Therapies in HIV-Infected Patients Who Have Never Received Anti-HIV Treatment

Completed· GSK logo

GSK·N/A·NCT00002216

A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug Treatment

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00006152·42 enrolled

Mycophenolate Mofetil and Abacavir Treatment in HIV Patients With Failed Anti-HIV Treatment

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00021489

HIV infection7 trials

Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00013520·1,125 enrolled

A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection

Completed· GSK logo

GSK·Phase 1·NCT00002183·60 enrolled

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000919·900 enrolled

Show 4 more trials

A Study of a Combination of Four Drugs in Patients With Recent HIV Infection

Completed· GSK logo

GSK·Phase 2·NCT00002233·30 enrolled

Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000872·55 enrolled

Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00102960·377 enrolled

A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00006154·165 enrolled

HIV5 trials

A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients

Completed· GSK logo

GSK·Phase 4·NCT00005764·100 enrolled

A Study of 1592U89 in HIV-Infected Patients

Completed· GSK logo

GSK·Phase 1·NCT00002388·48 enrolled

A Study of 1592U89 and Ethanol When Given Together to HIV-Infected Patients

Completed· GSK logo

GSK·Phase 1·NCT00002198

Show 2 more trials

A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001086·300 enrolled

Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy

Unknown status· GSK logo

GSK·Phase 3·NCT00008554·210 enrolled

13 more indications

Adult2 trials

A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults

Completed· Roche logo

Roche·Phase 2·NCT00002239·68 enrolled

A Study of 1592U89 in HIV-Infected Adults

Completed· GSK logo

GSK·N/A·NCT00002200

HIV-1 infection2 trials

Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection

Completed· GSK logo

GSK·Phase 3·NCT00440947·515 enrolled

An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen

Completed· GSK logo

GSK·N/A·NCT00002205

Completed· GSK logo

GSK·N/A·NCT00002197·250 enrolled

The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000865·32 enrolled

Combination Therapy1 trial

Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00006617·25 enrolled

Immune Response1 trial

Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00006578

Safety and Efficacy1 trial

A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects.

Completed· GSK logo

GSK·Phase 3·NCT00002199·550 enrolled

AIDS dementia1 trial

A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex

Completed· GSK logo

GSK·Phase 3·NCT00002163

Fat Metabolism1 trial

A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected Patients

Completed· GSK logo

GSK·Phase 3·NCT00002245

Trial1 trial

A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 1592U89

Completed·BBurroughs Wellcome·Phase 1·NCT00002141·18 enrolled

Metabolism1 trial

A Study to Test the Safety, Tolerance, and Metabolism of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy in Newborn Infants Born to HIV-1 Infected Women

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000864·60 enrolled

Side Effects1 trial

Changing to Nonprotease Inhibitor Treatment to Improve Side Effects

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00021463·342 enrolled

Sources

References

[1]
ClinicalTrials.gov — 57 trial records for Abacavir sulfate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Abacavir sulfate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Abacavir sulfate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GSK

Ziagen

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Effectiveness11 trials

Drug9 trials

Treatment7 trials

HIV infection7 trials

HIV5 trials

Adult2 trials

HIV-1 infection2 trials

Immune System2 trials

Adolescent2 trials

Children2 trials

Combination Therapy1 trial

Immune Response1 trial

Safety and Efficacy1 trial

AIDS dementia1 trial

Fat Metabolism1 trial

Trial1 trial

Metabolism1 trial

Side Effects1 trial

References

Drug Info

Quick Facts

Related News